Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE009 (AUS) (Dr. Novak)
· consented 2022-04-28
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-07-15 (study day 63); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: UNKNOWN; onset 2022-10-14 (study day 154); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 171); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 243); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 353); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 361); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.